SARC041 (Dedifferentiated Liposarcoma)

What is the Purpose of this Study?

We are doing this study to find out if a study drug called abemaciclib is a safe and effective option for patients with dedifferentiated liposarcoma that has grown or has spread.

What is the Condition Being Studied?

Dedifferentiated Liposarcoma

Who Can Participate in the Study?

Adults 18+ who are diagnosed with dedifferentiated liposarcoma that has grown or has spread.

For more information on who can participate in this study please contact the study team at 919-681-4768.

Age Group

What is Involved?

If you choose to join this study, you will get a random assignment to 1 of 2 groups:

  • One group will the study drug
  • The other group will get a placebo (inactive substance that has no drug in it)

In addition to the study drug or placebo, you will also take either a drug called envafolimab or a combination of envafolimab and doxorubicin. Whether or not you take envafolimab alone or in combination with doxorubicin will depend on when you join the study.

Study Details

Full Title
Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Principal Investigator
Professor of Medicine
Protocol Number
IRB: PRO00108915
NCT: NCT04967521
Phase III
Enrollment Status